Recon: Lilly scores approval for next-gen type 2 diabetes drug; FDA’s RWE pilot cites challenges in emulating RCTs
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy